Posted by Michael Wonder on 18 Dec 2020
Blueprint Medicines submits supplemental new drug application to FDA for Ayvakit (avapritinib) for the treatment of advanced systemic mastocytosis
17 December 2020 - Blueprint Medicines today announced the submission of a supplemental new drug application to the U.S. Food FDA for Ayvakit (avapritinib) for the treatment of adult patients with advanced systemic mastocytosis.
Ayvakit is a potent and selective inhibitor of D816V mutant KIT, the primary driver of systemic mastocytosis, and is being developed to treat advanced and non-advanced forms of the disease.
